Tag: Cerenovus

CERENOVUS Receives European Regulatory Approval For BRAVO Flow Diverter to Treat Intracranial Aneurysms.

BRUSSELS–(BUSINESS WIRE)–CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced today it has received European CE mark approval for its BRAVO Flow Diverter. The device is approved for use in the treatment of patients suffering from intracranial aneurysms. The device will divert blood flow from the aneurysm and […]

First Ischemic Stroke Patients Treated With EMBOTRAP II Revascularization Device Since Commercial Availability In U.S.

SAN FRANCISCO, July 24, 2018 /PRNewswire/ — CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced the first patients have been treated with its new EMBOTRAP II Revascularization Device since it became commercially available in the U.S. EMBOTRAP II is a next generation stent retriever used to capture and remove life-threatening blood clots […]

CERENOVUS Receives FDA Clearance For Next Generation Stent Retriever Device Used To Treat Ischemic Stroke

IRVINE, Calif., May 21, 2018 /PRNewswire/ — CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EMBOTRAP II Revascularization Device, a next generation stent retriever used to capture and remove life-threatening blood clots from […]


ARISE II Clinical Trial Results Presented at International Stroke Conference LOS ANGELES – Jan. 25, 2018 – EMBOTRAP® Device, a device designed to remove clots from the brain following an ischemic stroke, demonstrated high success rates in restoring blood flow and patients achieved high rates of functional independence, according to […]

Johnson & Johnson Medical Devices Companies Signals Commitment to Stroke Treatment With the Announcement of New Neurovascular Business

NICE, France, September 7, 2017 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* today introduced CERENOVUS,** its new neurovascular business, at the European Society of Minimally Invasive Neurological Therapy (ESMINT) 9th Annual Meeting. CERENOVUS, a name derived from the Latin words for ‘new’ and ‘brain’, will focus on delivering innovative therapies for hemorrhagic […]

Pulsar and Neuravi Now Part of J&J’s New Cerenovous Neurovascular Business

Johnson & Johnson rolls Pulsar Vascular, Neuravi into new Cerenovus neurovascular biz JULY 25, 2017 BY BRAD PERRIELLO  – MassDevice Johnson & Johnson (NYSE:JNJ) said yesterday that it’s medical device division is rolling the Pulsar Vascular and Neuravi acquisitions into a new neurovascular business dubbed Cerenovus. The New Brunswick, N.J.-based healthcare giant said the new brand, unveiled at […]